Alzamend Neuro Inc (NASDAQ: ALZN) received the FDA's "Study May Proceed" letter to initiate study AL001-BD01, a Phase 2A clinical study of AL001 for bipolar disorder type 1. The company expects the first patient to be dosed in the first quarter of 2024.
Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects identified a candidate dose that is unlikely to require therapeutic drug monitoring
Safety.
Alzamend Neuro Inc (NASDAQ: ALZN) received the FDA's "Study May Proceed" letter to initiate study AL001-BD01, a Phase 2A clinical study of AL001 for bipolar disorder type 1. The company expects the first patient to be dosed in the first quarter of 2024. Also Read: EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder. As a follow-up to our "IND submission" release in August, the FDA has granted us a "Study May Proceed" notifica
Alzamend Neuro, Inc. , a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease , bipolar disorder , major depressive disorder and.
Alzamend Neuro submits IND for bipolar disorder therapeutic healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.